The Trump administration moved to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. The change is expected to ease research restrictions but will not immediately legalize marijuana.
Athletes at the Milano Cortina 2026 Olympic Winter Games span a wide age range, from teenagers to competitors in their 50s. Research suggests hormonal changes may affect bone health and stress-fracture risk more directly than athletic performance.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
New research from Michigan State University reveals that differences in hormone-regulated monocytes explain why women experience longer-lasting chronic pain than men, with males producing more IL-10 to shut down pain signals.
Online telehealth company Hims & Hers withdrew plans to offer a $49 compounded oral semaglutide pill after FDA Commissioner Marty Makary called such products "illegal copycats" and Novo Nordisk filed a patent infringement lawsuit.
